Revvity

Revvity supports Cell & Gene Therapy developers in their discovery and pre-clinical stage with designing and optimizing the manufacturing of viral vectors (AAV, LV, AV), developing technologies that can boost therapy efficiencies like proprietary AAV capsids via evolution and rational design, or even LentiBOOST that can boost LV transduction.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

LentiBOOST™ Pharma-Grade: For research use only. Not for use in diagnostic procedures.